PREPAID EXPENSES AND OTHER CURRENT ASSETS

6 Months Ended

Jun. 30, 2026

Prepaid Expenses And Other Current Assets

PREPAID EXPENSES AND OTHER CURRENT ASSETS

NOTE 5 — PREPAID EXPENSES AND OTHER CURRENT ASSETS

Schedule of prepaid expenses and other current assets
	June 30, 2026		December 31, 2025
Contract research organization costs	$	127,106	$	-
Insurance & medical		59,485		126,034
Marketing		115,000		15,000
Research and development		36,753		33,333
Deferred offering costs		40,000		-
Materials and supplies		59,221		59,221
Note receivable		81,000		81,000
Other		52,191		48,426
Total	$	570,756	$	363,014

The Company enters into agreements with contract research organizations (“CROs”) to conduct and manage clinical trials in support of its research and development activities. Advance payments made under these arrangements are recorded as prepaid clinical trial expenses and are recognized as research and development expense as the related services are performed, based on management’s assessment of the progress toward completion of the applicable contractual services.

As of June 30, 2026, prepaid clinical trial expenses included approximately $127,000 of advance payments made under the Company’s agreement with its CRO in connection with the Company’s clinical trial evaluating the Gen-3 HALO device for the treatment of insomnia.